We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.

We have developed a diverse pipeline consisting of five distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet medical need where there are limited or no treatment options.

program pipeline